OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model

Primard C, Monchâtre-Leroy E, Del Campo J, et al.  Front Immunol. 2023;14:1188605. doi:10.3389/fimmu.2023.1188605

VFI headquarters and Geneva laboratories

Rue du Champ-Blanchod 4
1228 Plan-les-Ouates
Switzerland

VFI Lausanne laboratories

Route de la Corniche 5
1066 Epalinges
Switzerland

contact@vformulation.org
VFI on LinkedIn

© 2025 Vaccine Formulation Institute